AMGN logo Amgen +
Amgen
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Amgen's Revenue by Segment

In fiscal year 2024, Amgen's revenue by segment (products & services) are as follows:

  • Aranesp: $1.34 B
  • BLINCYTO: $1.22 B
  • ENBREL: $3.32 B
  • EVENITY: $1.56 B
  • KRYSTEXXA: $1.19 B
  • Kyprolis: $1.50 B
  • Nplate: $1.46 B
  • Otezla: $2.13 B
  • Other Products: $5.63 B
  • Product and Service, Other: $1.40 B
  • Prolia: $4.37 B
  • Repatha (evolocumab): $2.22 B
  • TEPEZZA: $1.85 B
  • TEZSPIRE: $972.00 M
  • Vectibix: $1.05 B
  • XGEVA: $2.23 B

Learn more about Amgen’s Revenue by Geography

Check out competitors to Amgen in a side-by-side comparison.

Explore additional financial metrics for Amgen.

Continue reading...

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2022, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.42 B in revenue, representing 5.4% of its total revenue.
  • ENBREL generated $4.12 B in revenue, representing 15.64% of its total revenue.
  • Evenity generated $787.00 M in revenue, representing 2.99% of its total revenue.
  • Kyprolis generated $1.25 B in revenue, representing 4.74% of its total revenue.
  • Neulasta generated $1.13 B in revenue, representing 4.28% of its total revenue.
  • Nplate generated $1.31 B in revenue, representing 4.97% of its total revenue.
  • Otezla generated $2.29 B in revenue, representing 8.69% of its total revenue.
  • Other Products generated $5.57 B in revenue, representing 21.16% of its total revenue.
  • Product and Service, Other generated $1.52 B in revenue, representing 5.78% of its total revenue.
  • Prolia generated $3.63 B in revenue, representing 13.78% of its total revenue.
  • Repatha (evolocumab) generated $1.30 B in revenue, representing 4.92% of its total revenue.
  • XGEVA generated $2.01 B in revenue, representing 7.65% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 21.16% of its total revenue.
The smallest segment for Amgen is the Evenity, which represents 2.99% of its total revenue.

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2023, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.36 B in revenue, representing 4.83% of its total revenue.
  • BLINCYTO generated $861.00 M in revenue, representing 3.05% of its total revenue.
  • ENBREL generated $3.70 B in revenue, representing 13.11% of its total revenue.
  • Evenity generated $1.16 B in revenue, representing 4.11% of its total revenue.
  • KRYSTEXXA generated $272.00 M in revenue, representing 0.96% of its total revenue.
  • Kyprolis generated $1.40 B in revenue, representing 4.98% of its total revenue.
  • Nplate generated $1.48 B in revenue, representing 5.24% of its total revenue.
  • Otezla generated $2.19 B in revenue, representing 7.76% of its total revenue.
  • Other Products generated $5.26 B in revenue, representing 18.67% of its total revenue.
  • Product and Service, Other generated $1.28 B in revenue, representing 4.54% of its total revenue.
  • Prolia generated $4.05 B in revenue, representing 14.36% of its total revenue.
  • Repatha (evolocumab) generated $1.64 B in revenue, representing 5.8% of its total revenue.
  • TEPEZZA generated $448.00 M in revenue, representing 1.59% of its total revenue.
  • Vectibix generated $984.00 M in revenue, representing 3.49% of its total revenue.
  • XGEVA generated $2.11 B in revenue, representing 7.49% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 18.67% of its total revenue.
The smallest segment for Amgen is the KRYSTEXXA, which represents 0.96% of its total revenue.

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2024, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.34 B in revenue, representing 4.02% of its total revenue.
  • BLINCYTO generated $1.22 B in revenue, representing 3.64% of its total revenue.
  • ENBREL generated $3.32 B in revenue, representing 9.92% of its total revenue.
  • EVENITY generated $1.56 B in revenue, representing 4.68% of its total revenue.
  • KRYSTEXXA generated $1.19 B in revenue, representing 3.55% of its total revenue.
  • Kyprolis generated $1.50 B in revenue, representing 4.5% of its total revenue.
  • Nplate generated $1.46 B in revenue, representing 4.36% of its total revenue.
  • Otezla generated $2.13 B in revenue, representing 6.36% of its total revenue.
  • Other Products generated $5.63 B in revenue, representing 16.84% of its total revenue.
  • Product and Service, Other generated $1.40 B in revenue, representing 4.18% of its total revenue.
  • Prolia generated $4.37 B in revenue, representing 13.09% of its total revenue.
  • Repatha (evolocumab) generated $2.22 B in revenue, representing 6.65% of its total revenue.
  • TEPEZZA generated $1.85 B in revenue, representing 5.54% of its total revenue.
  • TEZSPIRE generated $972.00 M in revenue, representing 2.91% of its total revenue.
  • Vectibix generated $1.05 B in revenue, representing 3.13% of its total revenue.
  • XGEVA generated $2.23 B in revenue, representing 6.66% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 16.84% of its total revenue.
The smallest segment for Amgen is the TEZSPIRE, which represents 2.91% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2022 2023 2024
Repatha (evolocumab) 4.92% 5.8% 6.65%
Product and Service, Other 5.78% 4.54% 4.18%
Aranesp 5.4% 4.83% 4.02%
ENBREL 15.64% 13.11% 9.92%
Evenity 2.99% 4.11% -
Kyprolis 4.74% 4.98% 4.5%
Neulasta 4.28% - -
Nplate 4.97% 5.24% 4.36%
Otezla 8.69% 7.76% 6.36%
Other Products 21.16% 18.67% 16.84%
Prolia 13.78% 14.36% 13.09%
XGEVA 7.65% 7.49% 6.66%
Vectibix - 3.49% 3.13%
TEPEZZA - 1.59% 5.54%
BLINCYTO - 3.05% 3.64%
KRYSTEXXA - 0.96% 3.55%
EVENITY - - 4.68%
TEZSPIRE - - 2.91%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Amgen.

In fiscal year 2024, the Other Products generated the most revenue ($5.63 B), and the TEZSPIRE generated the least revenue ($972.00 M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Aranesp revenue decreased -1.47% ($20.00 M) from $1.36 B (in 2023) to $1.34 B (in 2024).
  • BLINCYTO revenue increased 41.23% ($355.00 M) from $861.00 M (in 2023) to $1.22 B (in 2024).
  • ENBREL revenue decreased -10.31% ($381.00 M) from $3.70 B (in 2023) to $3.32 B (in 2024).
  • Evenity revenue decreased -100% ($1.16 B) from $1.16 B (in 2023) to $0.00 (in 2024).
  • EVENITY revenue increased 100% ($1.56 B) from $0.00 (in 2023) to $1.56 B (in 2024).
  • KRYSTEXXA revenue increased 335.66% ($913.00 M) from $272.00 M (in 2023) to $1.19 B (in 2024).
  • Kyprolis revenue increased 7.13% ($100.00 M) from $1.40 B (in 2023) to $1.50 B (in 2024).
  • Nplate revenue decreased -1.42% ($21.00 M) from $1.48 B (in 2023) to $1.46 B (in 2024).
  • Otezla revenue decreased -2.83% ($62.00 M) from $2.19 B (in 2023) to $2.13 B (in 2024).
  • Other Products revenue increased 6.97% ($367.00 M) from $5.26 B (in 2023) to $5.63 B (in 2024).
  • Product and Service, Other revenue increased 9.22% ($118.00 M) from $1.28 B (in 2023) to $1.40 B (in 2024).
  • Prolia revenue increased 8.05% ($326.00 M) from $4.05 B (in 2023) to $4.37 B (in 2024).
  • Repatha (evolocumab) revenue increased 35.9% ($587.00 M) from $1.64 B (in 2023) to $2.22 B (in 2024).
  • TEPEZZA revenue increased 313.17% ($1.40 B) from $448.00 M (in 2023) to $1.85 B (in 2024).
  • TEZSPIRE revenue increased 100% ($972.00 M) from $0.00 (in 2023) to $972.00 M (in 2024).
  • Vectibix revenue increased 6.2% ($61.00 M) from $984.00 M (in 2023) to $1.05 B (in 2024).
  • XGEVA revenue increased 5.35% ($113.00 M) from $2.11 B (in 2023) to $2.23 B (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Aranesp $1.42 B - $1.36 B
    4.15%
    		$1.34 B
    1.47%
    BLINCYTO - - $861.00 M - $1.22 B
    41.23%
    ENBREL $4.12 B - $3.70 B
    10.20%
    		$3.32 B
    10.31%
    Evenity $787.00 M - $1.16 B
    47.40%
    		- -
    EVENITY - - - - $1.56 B -
    KRYSTEXXA - - $272.00 M - $1.19 B
    335.66%
    Kyprolis $1.25 B - $1.40 B
    12.51%
    		$1.50 B
    7.13%
    Neulasta $1.13 B - - - - -
    Nplate $1.31 B - $1.48 B
    13.01%
    		$1.46 B
    1.42%
    Otezla $2.29 B - $2.19 B
    4.37%
    		$2.13 B
    2.83%
    Other Products $5.57 B - $5.26 B
    5.51%
    		$5.63 B
    6.97%
    Product and Service, Other $1.52 B - $1.28 B
    15.90%
    		$1.40 B
    9.22%
    Prolia $3.63 B - $4.05 B
    11.58%
    		$4.37 B
    8.05%
    Repatha (evolocumab) $1.30 B - $1.64 B
    26.16%
    		$2.22 B
    35.90%
    TEPEZZA - - $448.00 M - $1.85 B
    313.17%
    TEZSPIRE - - - - $972.00 M -
    Vectibix - - $984.00 M - $1.05 B
    6.20%
    XGEVA $2.01 B - $2.11 B
    4.87%
    		$2.23 B
    5.35%
    Total Revenue $26.32 B - $28.19 B
    7.09%
    		$33.42 B
    18.57%

    Frequently Asked Questions

    What was Amgen's largest product segment last year?

    In fiscal year 2024, Other Products revenue reached $5.63 Billion, representing 16.84% of Amgen's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for Amgen last year?

    The KRYSTEXXA segment is Amgen's highest growth segment, with a revenue growth of +335.66% in 2024 compared to 2023.

    Related company

    Revenue Ranking

    Revenue Ranking

    Related

    Submit feedback to Bullfincher